Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Introduction (11 mins)

Anna F. Farago, MD, PhD, explains the rationale for immune checkpoint inhibitor therapy in the clinical management of SCLC.
Anna F. Farago, MD, PhD
Taofeek K. Owonikoko, MD, PhD
Released: August 26, 2020 Expiration: No longer available for credit

This program is divided into short segments that you can review from the Activity landing page.
PreviousNext

Related Content

Phase I/II trial of mobocertinib for EGFR ex20ins+ advanced NSCLC in cohort of patients with disease progression after initial disease control on EGFR TKI therapy, from WCLC 2021 by Clinical Care Options (CCO)

Released: September 23, 2021

Initial analysis of amivantamab in patients with METex14+ metastatic or unresectable NSCLC from phase I CHRYSALIS trial, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 23, 2021

Downloadable summary slideset from a live CCO Webinar on immunotherapy for the treatment of patients across the spectrum of NSCLC

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 23, 2021

3-year update of CASPIAN showed sustained survival benefit of adding durvalumab to platinum-etoposide for first-line treatment in extensive-stage SCLC, presented at ESMO 2021 and reported by Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 23, 2021

Video Chapters


Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Genentech, a member of the Roche Group
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue